Wegovys active ingredient, semaglutide, mimics a natural hormone in your body called GLP-1 (glucagon-like peptide-1)
Groups where caution flags are highest People with uncontrolled high blood pressure or known cardiovascular disease
Each patient experiences a unique combination of symptoms before, during, and after treatment, and unresolved symptoms can impede functional improvement
A randomised controlled trial in 1,897 individuals living with type 2 diabetes compared the impact of three doses of tirzepatide (5mg, 10mg, and 15mg) compared to a once-weekly injection of 1mg semaglutide (Ozempic) on blood sugar levels
By contrast, a different meta-analysis reports small gains in sprint/strength ( 5% overall) driven by oral or supratherapeutic regimens, while these effects were not observed at WADA-permitted inhaled doses [5, 96, 97]